Minutes of the 2025 Annual General Meeting of Shareholders
Winnergy Medical Public Company Limited

Date, Time, and Venue

The 2025 Annual General Meeting of Shareholders of Winnergy Medical Public Company Limited (the "**Company**") was convened on April 24, 2025, at 14.00 hrs. via electronic meeting lived from the Conference Room located at the Company's head office No. 636/2, Soi Ramkhamhaeng 39 (Thepleela 1) Alley, Pracha Uthit Road, Wang Thonglang Sub-District, Wang Thonglang Distict, Bangkok 10310.

Directors present at the Meeting.

1. Asst Prof Dr. Terdsak Rojsurakitti	Chairman of the Board of Directors/Chairman of the Good Corporate Governance and Sustainability Committee/Chairman of the Nomination and Remuneration Committee/Independent Director
2. Mr. Chanat Sorakraikitikul	Chairman of the Audit Committee/Independent Director
3. Dr. Renu Ubol	Member of the Audit Committee/Member of the Good Corporate Governance and Sustainability Committee/Member of the Nomination and Remuneration Committee/Independent Director
4. Mr. Nattaphol Vimolchalao	Member of the Audit Committee/ Independent Director
5. Mr. Nanthiya Darakananda	Director/Chairman of the Risk Management Committee/Chairman of the Executive Committee/Member of the Nomination and Remuneration Committee/Chief Executive Officer
6. Mr. Amarin Pataranavi	Director
7 Mr. Tanakorn Vidhayasirinun	Director/Member of the Risk Management Committee
8. Ms. Jinhatha Panyasorn (D.D.S)	Director

The Company has a total of Eight (8) directors and all of whom were present at the Meeting, representing hundred (100) percent of the Company's directors.

Executive present at the Meeting

1. Mr. Rachan Arayawongchai	Member of the Risk Management Committee/ Executive Director/ Chief Finance Officer

In this Meeting, Mr. Athiphong Athiphongsaku, Ms. Hongyok Wimoonchat and Ms. Anusara Chatsoonthorn, representatives of the audit firm – ANS Audit Company Limited, were invited to attend the Meeting via electronic device in order to clarify matters related to the Company's financial statements.

Regarding the inspection of the Meeting and votes for each agenda item, Ms. Prathomporn Fungkhumdee, an independent legal consultant from PRO LEGAL & I.P. CO., LTD., who had no vested interest in the Company, was invited to attend the Meeting via electronic device, in order to ensure the transparency of voting procedures, and facilitating the Meeting to proceed in a transparent and lawful

manner and in accordance with the Company's Articles of Association and Corporate Governance Principles.

The Meeting commenced at 14.00 hrs.

Ms. Sita Potipipith, appointed by the Board of Directors to serve as the Moderator at the Meeting (the **"Moderator"**), welcomed all Shareholders attending the 2025 Annual General Meeting of Shareholders via electronic meeting. The Moderator thereafter informed the Shareholders that the Meeting was held electronically in compliance with the Emergency Decree on Electronic Meetings B.E. 2563 and the Notification of Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meeting via Electronic Means B.E. 2563. Accordingly, the Company had arranged an electronic meeting service provider having expertise and certified by the relevant agency. Additionally, the Company had arranged a representative from an outside legal consultant firm to inspect the voting procedures and facilitate the Meeting to proceed in a transparent and lawful manner and in accordance with the Articles of Association and the Corporate Governance Principles.

In this Meeting, the Company had determined a list of Shareholders eligible for participating the 2025 Annual General Meeting of Shareholders (Record Date) in accordance with the Securities and Exchange Act B.E. 2535 (Article 89/26) as March 13, 2025. Further details were available on website of the Stock Exchange of Thailand (SET) which showed important information of the Company, including a list of the first 10 shareholders and various news.

The Company had offered the Shareholders an opportunity to submit an additional agenda for the Meeting in accordance with the criteria stipulated by the Company in advance between November 8, 2024, and February 28, 2025. These had been disseminated via the Stock Exchange of Thailand's electronic channels. Nonetheless, no shareholder proposed an additional agenda item for the Meeting.

The quorum of Shareholders was as follows;

1. 1 share equivalent to 1 vote
2. The total number of attendees, attending personally or via proxy, of not less than 25 people
3. The total number of shares of not less than one-third (1/3) of the total paid-up shares or not less than 133,333,333.33 shares

The Moderator informed the Meeting that in the 2025 Annual Meeting of Shareholders, 9 Shareholders attended the Meeting via electronic devices, the total number of shares was 44,773,220 shares, and 18 proxies attended the Meeting and held 244,329,337 shares. In total, there were 27 Shareholders and proxies attending the Meeting with a total number of 289,102,557 shares. This constituted 72.2756% of the total paid-up shares as of March 13, 2025, the date determining the Shareholders' right to attend the 2025 Annual General Meeting of Shareholders (Record Date), which was set at 400,000,000 shares. The quorum required, as stipulated in the Company's Articles of Association, was duly met.

The Moderator then invited Asst. Prof. Dr. Terdsak Rojsurakitti, Chairman of the Board of Directors, who served as the Chairman of the Meeting (the **"Chairman"**), to open the 2025 Annual General Meeting of Shareholders.

The Chairman opened the meeting and thanked the Shareholders for their valuable time attending the 2025 Annual General Meeting of Shareholders. To ensure that the Meeting would proceed effortlessly, the Chairman assigned Ms. Wanwisa Soisawat, the Company's Secretary, to record the Meeting, and Ms. Sita Potipipith, the Moderator, to describe the steps and procedures for conducting the Meeting.

The meeting moderator informed the shareholders that this meeting is being recorded in the form of a video presentation. The Company will collect, use, and disclose personal data, including still images, audio, and video footage of all participants. The shareholders' meeting system is provided by Inventech Systems (Thailand) Co., Ltd. through the Inventech Connect platform, which has been officially registered as a digital platform service under the Royal Decree on Digital Platform Services Requiring Notification B.E. 2565 (2022) with the Electronic Transactions Development Agency (ETDA). The recording and data collection are for the purposes of meeting documentation, report preparation, meeting management, and other related processes. The moderator also explained the meeting procedures and guidelines as follows:

- In voting, each shareholder's vote would be proportional to the number of shares held and granted to them, implying 1 share equivalent to 1 vote.
- Shareholders and proxies using the proxy form A. and B. have only one way to vote, i.e., approve, disapprove, or abstain, without the possibility of separating the votes on each agenda. Nevertheless, the votes can be split into separate votes for a custodian shareholder who uses the proxy form C. If the grantor has already indicated his/her wish to vote, the votes will be recorded as stated in the proxy form from the time of commencing the Meeting.
- For Agenda 4, to consider and approve the appointment of directors in replacement of those due by rotation for 2025, the Company proposed to select the director individually according to Article 16 of the Company's Articles of Association.
- The vote-counting base for each agenda may not be equal due to the possibility of additional Shareholders and proxies attending during the Meeting.

Procedures for Voting, Vote Counting, Questioning, or Commenting were as follows:

1. The Meeting shall consider the matter in the order of Agendas specified in the invitation letter to the Meeting. In this regard, information will be presented on each agenda, allowing Shareholders to ask questions before voting, and the results will be reported at the conclusion of the vote count.
2. In voting, the Shareholders may choose the agenda item they wish to vote for. Then press the "Vote" button. The system will display all 3 voting channels: approve, disapprove, and abstain.

   The system displays all lists of Shareholders who have granted proxies to Shareholders or those who have been granted multiple proxies. Ballots are separated into individual user accounts for voting.

   To revoke a vote, press the "Revoke the Vote" button. For Shareholder who has not cast a ballot within the allotted time, the Company shall deem that such Shareholder has approved such agenda. Voting may be modified until the Company notifies a notice of closure and the Company allows 1 minute for voting. Once voting has concluded for each agenda item, the Meeting controller will process the vote, and the Secretary of the Meeting will announce the result, which will be given to the Meeting promptly before commencing the next agenda item.

   After the vote has concluded and the Secretary has announced the vote closed, the attendees are no longer eligible to vote on such agenda.

3. Shareholders for whom multiple Shareholders have granted proxies, please press "User Account" and "Change Account" to access the accounts of other Shareholders. No ballots will be removed from the voting pool.
4. By counting the votes, the Company will deduct disapproval and abstention ballots from the total number of votes when tallying the votes. The remaining ballots will be deemed as approval votes.
5. If a Shareholder decides to leave the Meeting prior to the ending of any vote, the Shareholder's vote will not be counted as quorum in such agenda and the vote will simultaneously not be counted in the remaining agenda. However, leaving the Meeting under any circumstances in any agenda will not prejudice the Shareholders' or proxies' right to return to a subsequent Meeting and vote in the next agenda in the system.
6. Questions or Comments in the Meeting

   Before casting vote in each agenda, the Company will provide attendees with at least 1 minute to ask questions or comment on matters relating to each agenda item, as deemed appropriate. For questions or comments on matters not directly relating to such agenda item, the Company asks for cooperation to provide questions or comments after the conclusion of agenda item 8, which is the last agenda. The Shareholders may select an agenda desired to question or comment, then select the "Question" button, and questions could be asked via two channels as follows:

   - Question Via text message: By typing the question then press “Submit”. The Company will answer questions in the Meeting room in the agenda concerning such matters. Nevertheless, if many questions are submitted, the Company reserves the right to select questions as appropriate, or
   - Question via VDO Conference: By pressing the "Question via VDO Conference" and press "OK" buttons to confirm your queue. Once authorized by the staff, turn on the camera and microphone. Before each query, attendees must notify the Company of their name, surname, and status as Shareholders or proxies so that the Company can keep a complete record of the Meeting's Minutes. If the VDO conference channel is interrupted during the Meeting, the shareholders are requested to ask the questions via text message instead.

   The Company reserves the right to turn off the image and voice of Shareholders who submit impolite questions or comments, make fraudulent or derogatory statements to other Shareholders, or violate any law, including violating the rights of others, disrupting the Meeting, or harassing other attendees.
7. In case many Shareholders desire to ask questions via the video conference system, the Shareholders are asked to submit their questions via text message for the staff to answer in order to maintain the appropriate duration of the Meeting. Due to the time limitation, if any questions cannot be answered during the Meeting, the Company will answer them at the end of the Meeting or will consider compiling the questions and answers of the directors for publication in the Meeting's Minutes and the Company's website.
8. If Shareholders experience any difficulties accessing the Meeting or voting system, please study and follow the instructions included with the Meeting’s invitation letter or select the "Help" menu in the system. Inventech Call Center staff can be reached via phone numbers and Line Official.
9. If the system fails during the Meeting, Shareholders will further receive an email instructing them to return to the Meeting through the backup system.

Before commencing to consider the agendas, the Moderator asked the Shareholders if they had any questions about the criteria and voting procedures. However, no shareholder posed questions. The Moderator then invited the Chairman of the Board of Directors who served as the Chairman of the Meeting to consider the agenda items included in the invitation letter to the Meeting.

Agenda 1 To acknowledge the Company Group's 2567 (2024) Annual Performance

The Chairman assigned Mr. Rachan Arayawongchai, the Chief Financial Officer (the "**CFO**") to report this matter.

– Table showing Revenues Structure –



Product group	2567		2566		Increase (Decrease)	
Sexual and Reproductive Care (SRC)	233.41	35.67%	204.86	33.81%	28.55	13.93%
Medical Blood Solution (MBS)	185.10	28.29%	161.23	26.61%	23.87	14.80%
Blood Safety Management (BSM)	158.08	24.16%	186.11	30.72%	-28.03	-15.06%
Cell & Molecular Technology (CMT)	59.02	9.02%	40.26	6.64%	18.76	46.60%
Consumer product group	18.75	2.87%	13.43	2.22%	5.32	39.61%
Total	654.36	100%	605.89	100%	48.47	8.00%

The CFO explained to the Meeting that for the year 2024, the Company had a total revenue from operations of 654.36 million Baht. Overall, all business groups of the Company have grown more than the previous year, except for the Blood Safety Management (BSM) products which have decreased due to higher competition on price in blood business, as well as suppliers' increase of price, resulting in the decrease of revenue. This year, the Company prepared a new product to be launched in 2025, which took over 2 years to prepare for registration. The Company expected that this product would generate more revenue to the team.

– Figure showing Mobile Blood Collection Project –




WINMED, leader of change, launched the first mobile blood collection unit in Thailand

The Mobile Blood Collection Project or the Project for collecting blood donations using mobile automatic machines: Presently, the Company has cooperated with the total of 11 hospitals covering districts in each major regions of Thailand, with a plan to cover more area this year. The Company cooperated with 4 big hospitals – Rajavithi Hospital, Ramathibodi Hospital, Central Chest Institute of Thailand, and H.R.H. Maha Chakri Sirindhorn Medical Center. In Southeastern region, the Company cooperated with 3 main hospitals – Khon Kaen Hospital, Roi Et Hospital, and Chaiyaphum Hospital. In Southern region, the Company cooperated with 3 hospitals – Vachira Phuket Hospital, Phra Chom Klao Hospital in Phetchaburi Province, and Songkhla Hospital. In Eastern region, the Company cooperated with Chonburi Hospital.

So far, the Company's Mobile Blood Collection units have collected over 11,000 units of blood.

– Figure showing MOU with the Company's partners –




Presently, for the Cervical Screening Project, the Company has been in contact with various Provincial Administrative Organizations (PAO) nationwide under the "Cervical Cancer" Screening in

Women at Risk Project and signed MOUs with 8 provinces in total, namely Nakhon Ratchasima, Kamphaeng Phet, Kanchanaburi, Prachinburi, Nakhon Si Thammarat, Phatthalung, Chanthaburi, and latest Nakhon Sawan, represented by the areas shaded in blue in the Figure above.

Furthermore, there were some provinces that have not signed an MOU but sent screening kits to Winmed Health Center, namely Udon Thani, Sakon Nakhon, Suphan Buri, Pathum Thani, and Bangkok, represented by the areas shaded pink in the Figure above. In addition, there were several other provinces in ongoing negotiations represented by the areas shaded in light blue in the Figure above, namely Chaiyaphum, Maha Sarakham, Samut Prakan, Yala, Pattani, Narathiwas, etc. This year, the Company expected good news from several provinces soon.

– Figure showing a list of the National Health Security Fund's disbursement –



This Figure showed a list of the National Health Security Fund's disbursement in 2024 fiscal year. Considering the private sector part, the Company was able to rank 1st in providing cervical cancer screening services among the private sectors that had disbursed, representing 47% from the first 10 lists of the private sector. Furthermore, when comparing the proportion of public sector and private sector, the private sector represented 70%, showing that the private sector was able to reach the people widely and work proactively, which were important factors contributing to an easy and quick access to medical checkup system, and more importantly, contributing to a further decrease of death by cervical cancer.

– Figure showing the first launch of AI Colposcopy in Thailand –



Moreover, the Company was the first and only provider importing into Thailand the colposcopy with AI-based system (AI COLPOSCOPY) which provide precision and high-resolution image. Users would not be required to be doctors and might be experts or trained personnel in this field. The Company's AI Colposcopy had been installed in the bestowed mobile unit vehicles of the Kuchinarai Crown Prince Hospital and used for inspection in the Red Cross Fair in Kalasin on February 26 - March 9.

– Figure showing the Winmed Cares Project –



The WINMED CARES Project under the National Health Security Office (NHSO)'s Reimbursement Policy, providing free cervical cancer screening for women aged 30-59 years

The WINMED CARES Project, continued from the previous year, has been a huge success. Several private agencies became partners with the Company and news of the Project were passed on. Consequently, the Project has currently had over 60,000 followers and more than 29,937 registrations.

– Figure showing Medical Checkup Units in Kanchanaburi PAO –



During year end, the Company, in cooperation with Kanchanaburi PAO, launched mobile medical checkup units, providing the screening of 5 diseases, namely cervical cancer screening, Hepatitis B virus infection screening, Hepatitis C virus infection screening, colon cancer screening, and providing HIV self-screening kits.

The feedback was great, resulting in the Company receiving good feedback this year, requesting for more provision of medical checkup units in each area.

– Figure showing Medical Checkup Units in Prachinburi PAO–



Furthermore, the Company provided mobile medical checkup units in Prachinburi which additionally provided Thermogram AI or breast cancer screening. The Company provided these units in December, last year, and received huge feedback from Prachinburi people. In the previous February, the

Company also signed a renewed MOU with the Prachinburi PAO to extend the cooperation in supporting medical checkup and screening of various diseases in the area.

– Figure showing the delivery of CliniMACS Prodigy –



The delivery of CliniMACS Prodigy to the Faculty of Medicine Siriraj Hospital, Division of Hematology, Department of Medicine

In 2024, the Company delivered the CliniMACS Prodigy, worth around 16 million Baht, to the Faculty of Medicine Siriraj Hospital, Division of Hematology, Department of Medicine, for the treatment of blood cancer patients.

Furthermore, in Quarter 1, the Company delivered an additional equipment to a public agency for the treatment of Thalassemia by gene therapy. In the future, the Company expected that the trend for treatment by cell and gene therapy would rise, resulting in a continuing growth in the Company's income in this business group.

– Figure showing the Thermogram.AI used for breast cancer screening –



The THERMOGRAM.AI Project signified breast cancer screening by new innovation using AI to analyze thermal images to screen for breast cancer, giving recipients privacy with no direct contact, no radiation, no pain during the screening process, and requiring only 15 minutes.

Most of the recipients were satisfied and passed the words onto their friends, making the Project receive good feedback and become another business with important role to reduce loss due to serious diseases by screening for breast cancer in initial phase, which would increase the chance of timely treatment to reduce the rate of breast cancer mortality.

– Figure showing the Company's partners in Thermogram.AI Project –




Presently, the Company has partnered with King Power for the provision of breast cancer screening and cervical cancer screening services for employees, providing medical checkup units at King Power's head office and branches. Moreover, the Company had negotiated with several companies to extend the provision of this kind of services further.

– Figure showing the sale of the BlackHole, a mosquito trap device, and marketing campaigns on online platforms –



Consumer products in the previous year were mosquito and insect trap devices. In the previous year, the Company gained more income partly from online platforms where the Company launched marketing campaigns and highly focus on, resulting in an increase of income, and it was likely to increase this year as new additional products would be on sale this year.

– Figure showing Consumer Marketing & Sales: PEDSUPAB –



For online platform, the Company's Consumer Marketing & Sales Team has launched a page entitled "PEDSUPAB" which currently had increase followers in every platform. Furthermore, the Company was invited to attend a fair organized by the Office of Public Health Communicable Disease, Health Department, on February 14, 2025.

– Figure showing WINMED's award on Corporate Governance Report of Thai Listed Companies 2024 and AGM Checklist 2024 –



In 2024, the Company obtained a score on Corporate Governance Report of Thai Listed Companies 2024 : CGR 2024 totaling 5 stars or "Excellent" for 2 years consecutively, which was more than the overall registered companies which have the total score of 84%, and became 1 of 367 companies obtaining over 90 points or Excellent out of 808 registered companies being assessed.

Moreover, the Company obtained a score on Annual General Meeting Checklist (AGM Checklist) 2024 totaling 5 medals or 100 full points from the Thai Institute of Directors (Thai IOD) for 2 years consecutively as well, which was considered as a success reflecting the Company's commitment to develop and improve the Company's performance. This year, the Company still committed to maintain standards and continue to receive this award further to boost confidence for Shareholders and investors in long term.

The Moderator provided further updates to the Meeting regarding the ongoing efforts to combat corruption and collusion within the Company. Currently, the Company was in the process of studying the overall certification process to consider participating in signing the integrity pledge with the Thai Private Sector Collective Action Coalition Against Corruption (CAC) with more progress than the previous year. However, the Company currently had an effective internal anti-corruption framework in place and a sufficient internal control system to prevent corrupt practices within the organization.

The Moderator subsequently offered shareholders and proxies the opportunity to inquire about the Company Group's 2567 (2024) Annual Performance Report. However, neither shareholders nor proxies asked questions or expressed their opinions on this agenda.


As there was no further additional question or comment being raised from the Shareholders, the Moderator thus informed the Meeting that this Agenda was for acknowledgement and voting was not required.

Resolution The Meeting acknowledged the Company Group's 2567 (2024) Annual Performance Report

Agenda 2 To approve the Company's Financial Statements for the year ended December 31, 2024

The Chairman appointed Mr. Rachan Arayawongchai, the CFO, to report this matter to the Meeting.

– Figure showing a summary of the auditor's report on the Company's Financial Statements for the year ended December 31, 2024 –




(For details please see below)

The CFO reported that for the Company's Financial Statements as of December 31, 2024, the certified auditor's report summary was "**without condition and without notice (unqualified)**". **The auditor stated that** "the consolidated and separate Financial Statements of Winnergy Medical Public Company Limited and its subsidiaries and of Winnergy Medical Public Company Limited, respectively, which comprised the consolidated and separate statements of financial position as of December 31, 2024, the consolidated and separate statements of comprehensive income, the consolidated and separate statements of changes in shareholders' equity, and the consolidated and separate statements of cash flows for the year then ended, were appropriately accurate in the keys matter in accordance with Thai Financial Reporting Standards (TFRSs)."

Key audit matters were those matters that, in my professional judgment, were of most significance in my audit of the consolidated and separate Financial Statements of the current year. These matters were addressed in the context of my audit of the consolidated and separate Financial Statements as a whole, and in forming my opinion thereon, I do not provide a separate opinion on these matters.


– Figure showing the Statement of Comprehensive Income in 2024 (B.E.2567) and 2023 (B.E. 2566) –



Statement of Comprehensive Income	2567		2566		Increase (Decrease)	
	(Million Baht)	Proportion	(Million Baht)	Proportion	(Million Baht)	% Change
รายได้จากการขายและบริการ	602.09	92.01%	586.44	91.75%	15.65	2.67%
รายได้ค่าเช่า	52.26	7.99%	52.74	8.25%	(0.48)	(0.90%)
รวมรายได้	654.36	100.00%	639.18	100.00%	15.18	2.37%
ต้นทุนขายและบริการ	(355.48)	(59.04%)	(350.70)	(59.80%)	(4.77)	1.36%
ต้นทุนค่าเช่า	(30.61)	(58.56%)	(30.05)	(56.98%)	(0.56)	1.86%
รวมต้นทุนขาย	(386.08)	(59.00%)	(380.75)	(59.57%)	(5.33)	1.40%
กำไรขั้นต้น	268.27	41.00%	258.43	40.43%	9.85	3.81%
รายได้อื่น	21.67	3.31%	10.24	1.60%	11.43	111.68%
ต้นทุนในการจัดจำหน่าย	(113.33)	(17.32%)	(101.13)	(15.82%)	(12.20)	12.07%
ค่าใช้จ่ายในการบริหาร	(130.47)	(19.94%)	(123.21)	(19.28%)	(7.26)	5.89%
กำไร (ขาดทุน) ก่อนต้นทุนทางการเงินและภาษี	46.14	7.05%	44.33	6.93%	1.81	4.09%
ต้นทุนทางการเงิน	(12.17)	(1.86%)	(9.07)	(1.42%)	(3.09)	34.09%
กำไรก่อนค่าใช้จ่ายภาษีเงินได้	33.97	5.19%	35.25	5.52%	(1.28)	(3.63%)
ค่าใช้จ่ายภาษีเงินได้	(4.71)	(0.73%)	(4.61)	(0.72%)	(0.10)	2.20%
กำไรสำหรับปี	29.26	4.46%	30.64	4.79%	(1.38)	(4.51%)

In 2024, the Company gained a comprehensive income from the operations totaling 654.36 million Baht, increasing from 2023 by 15.18 million Baht or equivalent to 2.37%. The Company had cost of sales totaling 386.08 million Baht, which when compared to the income equivalent to 59%, dropping 1.40% from the previous year. The Company had gross profit of 268.27 million Baht or equivalent to 41%. The Company had distribution costs totaling 113.33 million Baht, increasing by 12.20 million Baht, and administrative expenses totaling 130.47 million Baht, increasing by 7.26 million Baht from the previous year. The increased expenses were mostly due to the increase of job enlargement of the sales team and overall development expenses as per business expansion plan. The Company had net profit amounting to 29.26 million Baht or equivalent to 4.46%, resulting from the change in income and expenses demonstrated above.

– Figure showing the Company's Income from Operations –




A comparison of income from operations in 2024 (Y_2567) and 2023 (Y_2566) consisting of income from medical products, mosquito trap, and other income (other, ATK, and dividend)

Considering the income by group, the Company gained income from medical products totaling 635.6 million Baht, which increased from the same quarter of the previous year by 43.14 million Baht, reflecting the Company's growth.

The income from mosquito trap amounted to 18.75 million Baht, rising from the same quarter of the previous year by 5.41 million Baht as a result of the Company's adjustment of strategy to attract attention and boost sales via online media and campaigns via online platforms to drive buying motives.

In 2024, the Company gained no dividend income from investment in other businesses and no income from the sales of ATK. However, the profits from the sales of medical devices were recognized.

– Figure showing the consolidated balance sheet as of December 31, 2024 and December 31, 2023, and the differences –



งบแสดงฐานะทางการเงิน	ณ 31 ธ.ค. 2567		ณ 31 ธ.ค. 2566		ผลต่าง	
	งบตรวจสอบ		งบตรวจสอบ		ล้านบาท	% เทียบ 31 ธ.ค2566
	ล้านบาท	% ของยอดรวม	ล้านบาท	% ของยอดรวม		
สินทรัพย์						
สินทรัพย์หมุนเวียน	550.65	49.80%	518.87	53.06%	31.78	6.12%
สินทรัพย์ไม่หมุนเวียน	555.18	50.20%	459.00	46.94%	96.18	20.95%
รวมสินทรัพย์	1,105.83	100.00%	977.88	100.00%	127.95	13.08%
หนี้สินและส่วนของผู้ถือหุ้น						
หนี้สินหมุนเวียน	301.52	27.27%	276.20	28.24%	25.32	9.17%
หนี้สินไม่หมุนเวียน	172.17	15.57%	97.67	9.99%	74.50	76.28%
รวมหนี้สิน	473.69	42.84%	373.86	38.23%	99.83	26.70%
ส่วนของผู้ถือหุ้น	632.14	57.16%	604.02	61.77%	28.12	4.66%
รวมหนี้สินและส่วนของผู้ถือหุ้น	1,105.83	100.00%	977.88	100.00%	127.95	13.08%

Assets

As of December 31, 2024, the Company had total assets of 1,105.83 million Baht, increasing from those as of December 31, 2023 by 127.95 million Baht in total or equivalent to 13.08% growth. Details were as follows;

Current Assets

As of December 31, 2024, the Company had total current assets of 550.65 million Baht, increasing by 31.78 million Baht or equivalent to 6.12%. The main cause of the change was due to the increase in trade and other current receivables. The remains were the decrease of assets due to contracts and the management of inventory to be sufficient for distribution.

Non-Current Assets

Non-current assets grew by 96.18 million Baht, mainly resulting from the increase of lands and warehouses in accordance with the resolution of the 2024 Annual General Meeting of Shareholders on April 23, 2024 which included the purchase of inventory list.

Liabilities and Shareholders' equity

The Company had total liabilities amounting to 473.69 million Baht, increasing by 99.83 million Baht. The primary cause was long-term loans from financial institutions for the purchase of lands and warehouses abovementioned.

The Company had total Shareholders' equity amounting to 632.14 million Baht, increasing by 28.12 million Baht. This increase was a result of the rise of net profit in the previous year, deducted by the dividend payment as resolved at the Company's 2024 Annual General Meeting on April 23, 2024.

The full Financial Statements were disclosed in Form 56-1, One Report, for the fiscal year 2024, Section 3 Financial Statements (Page 204-267). These have been distributed to Shareholders along with the invitation letter to this Meeting, as detailed in Enclosure 1.

Thereafter, Mr. Chanat Sorakraikitikul, Chairman of the Audit Committee, reported the opinion of the Audit Committee to the Meeting as follows: The Audit Committee had considered and audited the Company's Financial Statements for the year ended December 31, 2024, which had been audited and signed by Mr. Atipong Athipongsakul, Certified Public Accountant No. 3500, the auditor of ANS Audit Company Limited. The Audit Committee resolved to submit to the Company's Board of Directors to propose to the 2025 Annual General Meeting of Shareholders for consideration and approval of the Company's Financial Statements for the year ended December 31, 2024.

The Moderator allowed Shareholders to ask questions and express their opinions regarding the 2024 Financial Statements for the fiscal year ended December 31, 2024. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the Financial Statements for the year ended December 31, 2024. This agenda required the approval of the Meeting by a majority vote of Shareholders attending and casting the votes at the Meeting.

Resolution The Meeting approved the Financial Statements for the year ended December 31, 2024, as reviewed by the Audit Committee, and duly audited and certified by the Company's auditor as proposed. The resolution was passed by the majority vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	289,102,557	100.00
Disapproved	0	0.00
Abstained	0	-
Total	**289,102,557**	**100.0000**

Agenda 3 To consider and approve the allocation of net profit as legal reserve fund and the distribution of dividend payment for the performance for the year 2024

(1) The Allocation of Net Profit as Legal Reserve Fund

The Chairman presented to the Meeting that in accordance with Section 116 of the Public Limited Company Act, B.E. 2535 (and amendments) (the "Public Limited Company Act") and Clause No.45 of the Company's Articles of Association, prescribing that "The Company shall allocate a certain amount of its annual net profit as a legal reserve fund for not less than 5 percent of its annual net profit, deducted by the accrued accumulative loss (if any) until this reserve amount is not less than 10 percent of its registered capital."

In 2024, the Company's net profit from the operating performance, as per separate Financial Statements for the year ended December 31, 2024, was **25,827,688.36** Baht. It was deemed appropriate to propose to the Meeting to approve the allocation of net profit from the 2024 operating performance as the legal reserve fund of **1,291,384.42** Baht (not less than 5% of 2024 net profit) as follows:

Items	2023	2024 (Propose Year)
1. Registered Capital (Baht)	200,000,000	200,000,000
2. Net profit as per separate Financial Statements (Baht)	30,598,490.19	25,827,688.36
3. Deduction for legal reserve fund (Baht)	1,529,924.51	1,291,384.42
4. Net profit as per separate Financial Statements (after reserve fund deduction) (Baht)	29,068,565.68	24,536,303.94
5. Legal reserve fund calculated as a percentage of net profit as per separate Financial Statements.	5.00%	5.00%
6. Legal accumulative reserve profit as a percentage of registered capital	7.35%	8.00%
7. Legal accumulative reserve profit in Baht	14,715,916.98	16,007,301.40

(2) The Payment of Dividend from the 2024 Operating Performance

The Chairman additionally reported to the Meeting that for the 2024 operating performance, Section 115 of the Public Limited Company Act and Clause No.44 of the Company's Articles of Association prescribed that "The Company is strictly prohibited from paying the dividend fund from any sum other than profit. In case of the Company's accumulative loss, dividend payment is not allowed". In addition, the Company had a policy to pay dividend to Shareholders at the rate of not less than 40% of the remaining net profit after deduction of all kinds of reserves as regulated by law and the Company, based on net profit as per separate Financial Statements. The dividend payment might be changed, subject to the Company's operating plans, financial status, liquidity, business expansion plans, other necessity and appropriateness in the future.

In 2024, the Company's net profit from operating performance as per separate Financial Statements for the year ended December 31, 2024 (after reserved fund deduction) was **24,536,303.94** Baht. It was deemed appropriate to propose to the Meeting for an approval of dividend payment, based on the Company's 2024 operating performance to Shareholders at the rate of **0.02475** Baht per share in the total amount of **9,900,000.00** Baht, or equivalent to 40.35% of the remaining net profit after reserved fund deduction. The Company's dividend payout ratio conformed to the ratio outlined in its dividend payment policy. In this regard, the comparison of dividend payments from the previous year appeared as follows:

Description of Dividend Payment	2023	2024 (Proposed Year)
1. Net profit as per separate Financial Statements (after reserve fund deduction) (Baht)	29,068,565.68	24,536,303.94
2. 40% of net profit as per separate Financial Statements	11,627,426.27	9,721,714.52

Description of Dividend Payment	2023	2024 (Proposed Year)
(after reserve fund deduction) (Baht)		
3. Total amount of dividend payment (Baht)	11,800,000.00	9,900,000.00
4. Dividend per share (Baht: Share)	0.0295	0.02475
5. Dividend payment rate per remaining net profit from reserve fund deduction (%)	40.59	40.35
6. Total number of shares entitled for receipt of dividend payment (share)	400,000,000	400,000,000
7. Par value of share (Baht: Share)	0.50	0.50

Thereby, the Company's dividend payout ratio conformed to the ratio outlined in its dividend payment policy.

The Moderator allowed Shareholders to ask questions and express their opinions regarding the allocation of profit as legal reserve fund and the distribution of dividend payment for the 2024 operating performance. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the allocation of profit as legal reserve fund and the distribution of dividend payment for the 2024 operating performance as proposed. This Agenda required the approval of the Meeting by a majority vote of Shareholders attending and casting the votes at the Meeting. If the votes were to be equal, the Chairman was entitled to another casting vote.

Resolution The Meeting approved the allocation of the 2024 net profit as a legal reserve fund in the amount of 1,291,384.42 Baht or equivalent to 5% of the 2024 net profit. Accordingly, the total amount of legal reserve fund presently amounting to 16,007,301.40 Baht or equivalent to 8.00% of the Company's registered capital. The Meeting also approved the dividend payment for the year 2024 derived from the 2024 operating performance (separate Financial Statement) as of December 31, 2024, at the rate of 0.02475 Baht per share. In this regard, an individual Shareholder shall be deducted 10% withholding tax and entitled to a dividend tax credit at the rate of 20/80.

The Record Date determining the list of Shareholders entitled to receive the dividend payment was stipulated as March 13, 2025, and the dividend payment date was set on May 21, 2025.

The resolution was passed by a unanimous vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes

Approved	289,102,557	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	**289,102,557**	**100.0000**

Agenda 4 To approve the appointment of directors to replace those who retired by rotation

For this Agenda, the Chairman asked the Directors whose terms have expired to temporarily leave the Meeting while this Agenda was being discussed to adhere to the Good Corporate Governance Principles and to allow the Shareholders to vote freely.

Section 71 of the Public Limited Company Act B.E. 2535, and Clause No.17 of the Company's Articles of Association, prescribed that in each Annual General Meeting of Shareholders, one-third (1/3) of the total number of directors at that moment shall be retired. In case the number of directors could not be divided by one-third (1/3), the number of retired directors shall be the closest to one-third (1/3). The directors to be retired in the first and second year after company registration shall draw lots. For later years, the director taking the position for the longest term shall be retired.

The Board of Directors, therefore, proposed that the Meeting consider reappointing Directors whose terms have expired to serve as the Company's Directors for another term. The Shareholders could review the information about the Directors whose terms have expired and who were nominated for re-appointment in the documents sent along with the invitation letter to the Meeting.

The list of Directors to be retired by rotation were as follows;

Name	Position
1. Mr. Nanthiya Darakananda	Director/Chairman of the Risk Management Committee/ Chairman of the Executive Committee/Member of the Nomination and Remuneration Committee/Member of the Good Corporate Governance and Sustainability Committee/Chief Executive Officer
2. Dr. Renu Ubol	Member of the Audit Committee/Member of the Nomination and Remuneration Committee/Member of the Good Corporate Governance and Sustainability Committee/ Independent Director
3. Mr. Amarin Pataranavi	Director

Primary information about the directors were as follows:

1. **Mr. Nanthiya Darakananda** had served as an Independent Director for 7 years and 2 months. If reappointed to serve for another term, Mr. Nanthiya Darakananda would serve as Director in total of 10 years and 2 months. Mr. Nanthiya Darakananda had expertise and was highly appropriate to be considered reappointed to serve as Director for another term.
2. **Dr. Renu Ubol** had served as an Independent Director for 5 years and 7 months. If reappointed to serve for another term, Dr. Renu Ubol would serve as Director in total of 8

years and 7 months. The Nomination and Remuneration Committee has conducted a comprehensive screening and evaluation process, considering various factors and the Company's business needs, and viewed that it was highly appropriate to reappoint Dr. Renu Ubol as an Independent Director for another term as Dr. Renu Ubol had medical expertise, knowledge, and provided advisory contributions to the Company's business.

3. **Mr. Amarin Pataranavi** had served as a Director for 5 years and 9 months If reappointed to serve for another term, Mr. Amarin Pataranavi would serve as Director in total of 8 years and 9 months. Mr. Amarin Pataranavi had an expertise in laws and regulations, equipped with knowledge, and provided advisory contributions to the Company's business.

Thereafter, the Chairman proposed that the Meeting consider approving the reappointment of the 3 Directors abovenamed whose terms already expired to serve another term as these individuals have demonstrated exemplary performance throughout their terms as the Board Members, and in order to ensure the continuity of the Company's management and to maximize Shareholders' benefit.

Furthermore, in the process of selecting the Directors, the Company has provided an opportunity for Shareholders to nominate qualified candidates for election as the Company's Directors. This information was disseminated through the website of the Stock Exchange of Thailand and the Company's website, where the criteria for nominations were also outlined. The Shareholders were able to nominate individuals with appropriate qualifications for election as the Company's Directors between November 8, 2024, and February 28, 2025. However, upon the expiration of such period, there was no Shareholder nominating any candidate to be the Company's Directors.

The nomination of the aforenamed Directors has been approved in accordance with the resolution of the Nomination and Remuneration Committee Meeting No. 1/2567, held on February 26, 2025. The Board of Directors has also considered the greatest interest of the Company, as well as the abilities, qualifications, experience, and expertise, in accordance with the components of the Company's Board of Directors. The Company's Board of Directors has therefore proposed the re-appointment of the 3 individuals whose terms have expired, allowing them to serve another term as these individuals were equipped with knowledge and ability which would be beneficial and supportive to the success of the Company's business.

To adhere to the Good Corporate Governance principles, it was resolved that the 2025 Annual General Meeting of Shareholders shall re-appoint the Directors whose terms have expired, allowing them to serve another term. Individual Director nominees will be presented for Shareholders to vote on, providing Shareholders with the genuine opportunity to select Directors.

The Moderator allowed the Shareholders to ask questions and express their opinions regarding the appointment of Directors to replace those who retired by rotation. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the appointment of Directors to replace those who retired by rotation

individually. This Agenda required the approval of the Meeting by a majority vote of Shareholders attending and casting votes at the Meeting.

Resolution The Meeting approved the re-appointment of each director, replacing those retired by rotation to hold the Company's director position for another term individually. The resolution was passed by majority votes of shareholders attending the meeting and casting their votes as follow:

1. Mr. Nanthiya Darakananda
Director/Chairman of the Risk Management Committee/Chairman of the Executive Committee/Member of the Nomination and Remuneration Committee/Member of the Good Corporate Governance and Sustainability Committee/Chief Executive Officer

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	284,767,797	100.0000
Disapproved	0	0.0000
Abstained	4,334,760	-
Total	**289,102,557**	**100.0000**

2. Dr. Renu Ubol
Independent Director/Member of the Audit Committee/Member of the Nomination and Remuneration Committee/Member of the Good Corporate Governance and Sustainability Committee

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	288,722,457	99.9999
Disapproved	100	0.0000
Abstained	380,000	-
Total	**307,863,760**	**100.0000**

3. Mr. Amarin Pataranavi
Director

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	288,802,557	100.0000
Disapproved	0	0.0000
Abstained	300,000	-
Total	**289,102,557**	**100.0000**

Agenda 5 To approve the remuneration of the Company's Directors for the year ended December 31, 2025

The Chairman presented to the Meeting that Section 90 of the Public Limited Company Act B.E.2535 (and amendments) and Clause No.22 of the Company's Articles of Association prescribed that the Company's directors are entitled to receive remunerations in form of prize reward, meeting allowance, gratuity, bonus, or other remunerations as the shareholders' meeting consider and resolve. However, the directors' remuneration should align with the Company's performance, duties, responsibilities, and performance of each director and should be reviewed annually.

In this regard, the Nomination and Remuneration Committee Meeting No. 1/2567, held on February 26, 2025, had reviewed and determined remuneration of the Company's Directors and sub-committee for the year 2025, considering the conformity to renumeration of the board of directors of other listed companies in industry with similar size, the Company's operating performance, the Director's performance and responsibilities. In addition, such amount of remuneration was within the mean based on the survey of remuneration of Thai listed companies studied by the Thai Institute of Directors (IOD) in December 2024. Therefore, it was resolved to propose to the Meeting to consider approving the determination of remuneration of the Directors for year 2025 within the budget not exceeding 800,000 Baht. Details were as follows;

Position		Meeting Allowance (Baht/Meeting/Person)) [1]	
		2024	**2025 (Proposed Year)**
The Board of Directors	**Chairman**	30,000	30,000
	Directors	15,000	15,000
The Audit Committee	**Chairman**	20,000	20,000
	Members	15,000	15,000
Other Sub-Committees [2]	**Chairman**	15,000	15,000
	Members	10,000	10,000

Notes

[1] Executive Director, consultant, employee or the representative of major shareholders are not entitled to receive the remuneration as Director or member of the sub-committees

[2] Other Sub-Committees refer to the Nomination and Remuneration Committee, the Executive Committee, the Risk Management Committee and the Good Corporate Governance and Sustainability Committee.

Subsequently, the Moderator informed the Meeting that there were Board Members who were Shareholders of the Company and had vested interests in this Agenda, namely:

(Data as of March 13, 2025)

First-Last Name	Amount of share(s)	Calculated as (%)
1. Asst Prof Dr. Terdsak Rojsurakitti	400,000	0.1%
2. Dr. Renu Ubol	380,000	0.095%
3. Mr. Nattaphol Vimolchalao	100,000	0.025%
4. Mr. Chanat Sorakraikitikul	100	0.000025%

Therefore, these four Board Members were considered interested parties and were not entitled to vote in this Agenda. As for the Company's Directors who served as executives and received regular salaries, they would not receive remuneration as proposed above. Hence, they were not deemed as interested parties in this Agenda.

The Moderator allowed the Shareholders to ask questions and express their opinions regarding the remuneration of the Company's Directors for the year 2025. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the remuneration of the Company's Directors for the year 2025. This Agenda required the approval of the Meeting by the votes of not less than two-thirds (2/3) of the total votes of the Shareholders presenting at the Meeting.

Resolution The Meeting approved the determination of the Board of Directors remuneration for the year ended December 31, 2025 within the budget not exceeding 800,000 Baht. The remuneration consisted of the meeting allowance and other benefits such as welfare as per the Company's regulations. The Executive Directors were excluded from this remuneration. Details of the remuneration were as follows:

The Board of Directors Remuneration for the year 2025

Position	Meeting Allowance (Baht/Meeting/Person)
The Board of Directors	
- Chairman	30,000
- Directors	15,000
The Audit Committee	
- Chairman	20,000
- Members	15,000
Other Sub-Committee	
- Chairman	15,000
- Members	10,000

The resolution of the 2025 Board of Directors remuneration was passed by a vote of not less than two-thirds (2/3) of the Shareholders attending the Meeting. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	288,222,457	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
No right to vote	880,100	-
Total	**289,102,557**	**100.0000**

Agenda 6 To approve the appointment of auditor and determine the audit fee for the year ended December 31, 2025

The Chaiman presented to the Meeting that Section 120 of the Public Limited Company Act B.E.2535, prescribed that "The Annual General Meeting of Shareholders shall appoint the Company's auditor and determine the audit fee each year. Previous auditor can be re-appointed." and Clause No.36 of the Company's Articles of Association regulated that the Annual General Meeting of Shareholders shall appoint the Company's auditor and determine the audit fee each year.

For year 2025, the Company had proposed and inquired the fee proposal for the selection of certified public accountant and appointment of auditor of the Company and its subsidiary companies. The Audit Committee had considered based on the auditor's operating performance, independence and remuneration, and viewed that ANS Audit Co., Ltd. of which its audit personnels were the Company's auditors in 2024 was the auditing firm with good knowledge and understanding on the businesses of the Company group and offered reasonable audit fee. It was then considered to propose ANS Audit Co., Ltd., the certified public accountant company as approved by the Office of the Securities and Exchange Commission to be the Company's auditor for the year 2025.

1. Auditors' Name

Auditor Name	CPA No.	Number of Year Providing Audit Services for the Company
1. Mr. Vichai Rujitanon	4054	-
2. Miss Kulthida Phasuraku	5946	-
3. Mr.Yutthapong Cheumuangphan	9445	-
4. Miss Atchara Suknaibaibun	4642	-
5. Miss Patcharee Sirisongsilp	9037	-

It was mandated that any of the auditors perform auditing duties and provide an auditor's opinion for the Company's Financial Statements for the year 2025. If the auditors mentioned above were unable to perform their duties, ANS Audit Co., Ltd. shall be entitled to appoint other certified auditors of ANS Audit Co., Ltd.

2. Audit Fee

Information for consideration	2024	2025 (Proposed Year)
1. Audit fee	2,120,000	2,070,000
2. Non-Audit Fee	Nil	Nil
Total	**2,120,000**	**2,070,000**

These audit fees did not include other service fees actually incurred in the course of auditing work (Non-Audit Fee), including any costs and expenses actually incurred during the provision of service (Out of Pocket Expense).

3. The relationship between the Company and those auditors

The abovenamed auditors did not have any relationship or conflict of interest with the Company, its subsidiaries, managements, major Shareholders, or any related parties. Therefore, they were independent in auditing and providing opinions on the Company's Financial Statements.

In this regard, the Audit Committee considered the criteria of the Public Limited Company Act B.E. 2535 and the Notification of the Capital Market Supervisory Board, including the qualification, eligibility of the auditor, as well as the audit fee and viewed that ANS Audit Co., Ltd. performed in accordance with the standard on auditing satisfactorily and provided useful opinions to the Company. In addition, it possessed comprehensive qualification, demonstrated a good understanding of the business of the Company group, and maintained no relationships with or vested interests in the Company, its subsidiaries, managements, major Shareholders, or related parties. Therefore, it had sufficient independence to audit and provide opinions on the Company's Financial Statements. Additionally, its audit fee was reasonable. Therefore, it is resolved to propose to the Board of Directors to propose to the 2025 Annual General Meeting of Shareholders to consider appointing the auditors and fixing the audit fee as presented above.

The Moderator then allowed the Shareholders to ask questions and express their opinions regarding the appointment of auditor and determine the audit fee for the year ended December 31, 2025. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the appointment of auditor and determine the audit fee for the year ended December 31, 2025. This agenda required the approval of the Meeting by a majority vote of the Shareholders attending and casting the votes at the Meeting.

Resolution The Meeting approved the appointment of the auditors from ANS Audit Company Limited to be the Company's auditors for the year 2025. The list of auditors was as follows

1. Mr. Vichai Ruchitanont Certified Public Accountant 4054 and/or
2. Ms. Kultida Pasurakul Certified Public Accountant 5946 and/or
3. Mr. Yuttapong Chuamuanpan Certified Public Accountant 9445 and/or
4. Ms. Atchara Suknaibaiboon Certified Public Accountant 4642 and/or
5. Miss Patcharee Sirisongsilp Certified Public Accountant 9037

Assigned any of the auditors named above to perform the audit or review and provide an opinion on the Company's Financial Statements, including those of its subsidiaries. If the auditors

named above were unable to perform their duties, ANS Audit Co., Ltd. shall assign other certified auditors of ANS Audit Co., Ltd. to act on their behalf.

The audit fee for the year 2025 was fixed at 1,750,000 Baht, and the audit fee for the subsidiaries in the amount of 320,000 Baht. The total amount equaled 2,070,000 Baht, excluding other service fees (non-audit fees) which the Company would pay as actually incurred. The resolution was passed by the majority vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	289,102,557	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	**289,102,557**	**100.0000**

Agenda 7 To consider other matters (if any)

The Chairman stated that opening other agendas for shareholders to inquire, discuss, and/or provide suggestions to the Board of Directors and/or management on matters beyond those proposed as agenda items for consideration was allowed. However, if the Shareholders wished to have other matters considered and resolved beyond those specified in the invitation letter to the Meeting, they must comply with the conditions of the law as stipulated in Section 105, Paragraph Two of the Public Limited Company Act B.E. 2535, stating "After the Meeting has considered and concluded according to the first paragraph, shareholders holding in aggregate not less than one-third of the total number of shares sold may request that the Meeting consider other matters beyond those specified in the invitation letter to the Meeting".

Since this Agenda pertained to other matters and the Company had no other items to propose for consideration by today's Meeting, the Chairman then opened the floor to the Shareholders to ask questions about any other matters related to the Company. There were Shareholders who had questions and comments, and the key points summarized as follows:

The Moderator informed the Meeting that if there were no further questions from the Shareholders on this final Agenda, the Moderator then provided details on the Meeting's Minutes preparation process to ensure compliance with good practices. After the Meeting concluded, the Company would announce the resolutions made at the Meeting through the Stock Exchange's news dissemination system within the next business day. Additionally, the Company would prepare the Meeting's Minutes within 14 days from the Meeting Date and submit to the Stock Exchange via the Stock Exchange's information dissemination system, as well as publish on the Company's website to ensure that Shareholders would be informed of the Meeting outcome and could verify the accuracy of the Meeting.

There was no further question. The Chairman therefore thanked all Shareholders for attending the Meeting and declared the Meeting adjourned at 15.34 hrs.

Sign_____-*Signature*-_____Chairman of the Board of Directors
(Asst Prof Dr. Terdsak Rojsurakitti)

Sign_____-*Signature*-_____Secretary / Minutes Recorder
(Ms. Wanwisa Ruenlapa)